Holen Sie sich die Stockscreener-App
18.93
0.47%
-0.09
Handel nachbörslich:
18.93
Eton Pharmaceuticals Inc Aktie (ETON) Neueste Nachrichten
Eton Pharmaceuticals (NASDAQ:ETON) Trading Up 6%What's Next? - MarketBeat
Jefferies Financial Group Inc. Invests $1.92 Million in Eton Pharmaceuticals, Inc. $ETON - MarketBeat
Eton Pharmaceuticals (ETON) Expected to Announce Earnings on Thursday - MarketBeat
Chipmakers Recap: Is Eton Pharmaceuticals Inc still a buy after recent gainsWeekly Stock Report & Daily Volume Surge Signals - baoquankhu1.vn
Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Given Consensus Rating of "Hold" by Brokerages - MarketBeat
Will Eton Pharmaceuticals Inc. stock deliver strong dividend growth2026 Rallies & Daily Volume Surge Signals - Naître et grandir
Retail Surge: Can Eton Pharmaceuticals Inc lead its sector in growth2025 Trading Recap & Long-Term Capital Growth Strategies - baoquankhu1.vn
HC Wainwright Analysts Boost Earnings Estimates for ETON - MarketBeat
HC Wainwright Issues Pessimistic Outlook for ETON Earnings - MarketBeat
Eton Pharmaceuticals (NASDAQ:ETON) Given New $30.00 Price Target at Craig Hallum - Defense World
Eton Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, March 19, 2026 - The Manila Times
Eton Pharmaceuticals Announces Fourth Quarter and Full Year 2025 Financial Results Date and Conference Call Details - Quiver Quantitative
Eton Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, ... - Bluefield Daily Telegraph
Eton inks deal to sell its 10th rare disease drug - Crain's Chicago Business
Craig Hallum Issues Positive Forecast for Eton Pharmaceuticals (NASDAQ:ETON) Stock Price - MarketBeat
Eton Pharmaceuticals price target raised to $30 from $29 at Craig-Hallum - TipRanks
Eton Pharmaceuticals acquires U.S. rights to hemangioma drug By Investing.com - Investing.com Canada
Eton Pharmaceuticals acquires U.S. rights to hemangioma drug - Investing.com Australia
Eton Gains on Acquiring Right to Baby Medicine - Baystreet.ca
Eton Pharmaceuticals Acquires US Commercialization Rights to Pierre Fabre's Hemangeol - marketscreener.com
HC Wainwright Forecasts Strong Price Appreciation for Eton Pharmaceuticals (NASDAQ:ETON) Stock - MarketBeat
Eton Pharmaceuticals Acquires U.S. Rights to HEMANGEOL - TipRanks
Eton Pharmaceuticals, Inc. announced that, in addition to the acquisition of core assets, the company also plans to purchase approximately $1.5 million worth of inventory products at the time of transaction closing. - Bitget
Eton Pharmaceuticals Secures U.S. Rights to HEMANGEOL® for Infantile Hemangioma Treatment, Launching May 1st - Quiver Quantitative
Eton Pharmaceuticals Expands Rare Disease Portfolio Through Acquisition of U.S. Commercialization Rights to HEMANGEOL® (propranolol hydrochloride) Oral Solution - The Manila Times
Understanding Momentum Shifts in (ETON) - Stock Traders Daily
Lumbard & Kellner LLC Buys New Holdings in Eton Pharmaceuticals, Inc. $ETON - MarketBeat
Eton Pharmaceuticals Expands Rare Disease Portfolio Through - GlobeNewswire
Eton Pharmaceuticals (NASDAQ: ETON) licenses U.S. HEMANGEOL rights in orphan drug deal - Stock Titan
Eton Pharmaceuticals, Inc. has signed a licensing agreement to successfully acquire the exclusive U.S. marketing rights for Hemangeol oral solution from Pierre Fabre Medicament Sas. - Bitget
Eton Pharmaceuticals' DESMODA Receives FDA Approval - Intellectia AI
US FDA approves Eton Pharma’s hormonal disorder drug - 1470 & 100.3 WMBD
Eton Pharmaceuticals Receives FDA Approval for New Drug Launch - Intellectia AI
Eton Reports US FDA Approval for Desmoda Oral Solution - marketscreener.com
Eton Pharmaceuticals Wins FDA Approval for DESMODA Therapy - TipRanks
Eton wins FDA nod for rare disorder therapy Desmoda (ETON) - Seeking Alpha
US FDA approves Eton's liquid therapy for rare water-balance disorder - Reuters
US FDA approves Eton Pharma's hormonal disorder drug - AOL.com
Eton Pharmaceuticals Launches DESMODA™, First FDA-Approved Oral Solution for Central Diabetes Insipidus - Quiver Quantitative
Eton Pharmaceuticals Announces U.S. FDA Approval for DESMODA™ (desmopressin acetate) Oral Solution - GlobeNewswire
ETON Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
FDA To Decide On ET-600 On February 25: Will It Mark Eton's Ninth Commercial Product? - RTTNews
Eton Pharmaceuticals to Participate at Leerink Partners Global Healthcare Conference on Wednesday, March 11th - The Manila Times
February 2026's Top Growth Companies With Insider Influence - simplywall.st
Eton Pharmaceuticals submits NDA for its diabetes insipidus treatment - MSN
What are Eton Pharmaceuticals Inc.’s technical support levelsJuly 2025 Big Picture & Real-Time Stock Entry Alerts - mfd.ru
Volatility Watch: Is Eton Pharmaceuticals Inc a cyclical or defensive stockGap Up & Safe Entry Zone Identification - baoquankhu1.vn
Activity Recap: Is Eton Pharmaceuticals Inc. still a buy after recent gains - mfd.ru
Eton Pharmaceuticals (ETON) Investor Outlook: A Small-Cap Biotech with a 78.68% Potential Upside - DirectorsTalk Interviews
What drives Eton Pharmaceuticals Inc.’s stock priceEarnings Miss & Weekly High Potential Stock Alerts - mfd.ru
We Might See A Profit From Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Soon - simplywall.st
Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Given Average Rating of "Hold" by Analysts - MarketBeat
Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Given Average Rating of “Hold” by Analysts - Defense World
Analysts Are Bullish on These Healthcare Stocks: Eton Pharmaceuticals (ETON), HealthStream (HSTM) - The Globe and Mail
1.15%
3.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):